Net revenue approaches US$100M since launch. NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: ...

SOUTH SAN FRANCISCO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to participate in ...

A 2026 informational overview of Metabo Drops coffee metabolism drop marketing claims, proprietary blend label disclosures, ingredient dosage research context, pricing structure, 60-day guarantee ...

Interested parties may register for the conference call using the following link: Nanox Q4 2025 Call The live webcast of the conference call may be accessed by using the following link: Nanox Q4 2025 ...

Pfanstiel will depart his role as Executive Vice President, Chief Financial Officer, and Treasurer to pursue an opportunity outside the Company. He will remain with the Company through May 1, 2026 to ...

Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today ...

Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today announced the ...

About Immuneering Immuneering is a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive. The Company is developing an entirely new category of cancer ...

The patent, once granted, is expected to protect major European markets, further enhancing Silo’s strategic positioning as it advances its pipeline. The Company is evaluating Unitary Patent protection ...

AMERICAN FORK, Utah, April 06, 2026 (GLOBE NEWSWIRE) -- DIBS AI ®, a division of OrthoSelect, announces the launch of Version 9.0 of its award-winning, patented orthodontic treatment software.

YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses - YUVIWEL is now commercially ...

Includes novel proteomic and genomic approaches to oncology therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing. LOUISVILLE, Colo., April 06, ...